source
- EMA launches consultation to streamline nonclinical development for life-threatening diseasesEMA announced a public consultation on proposals to accelerate the nonclinical phase of drug development for diseases that are severely debilitating or life‑threatening. The agency aims to reduce…
- Novo Nordisk board members disclose share vesting transactionsNovo Nordisk issued a regulatory announcement on 6 August 2026 detailing share transactions by its board members, executives and related persons, as required by EU market abuse regulation. The fil…